# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Now Accessible To Over 116M Commercially Covered Lives; First FDA-Approved PCAB For GERD Treatment In Over 30 Years, Says Phath...
JP Morgan Chase is reportedly gauging investor interest in a possible issuance of high-yield bonds by Walgreens Boots Alliance,...
Cantor Fitzgerald analyst Sarah James reiterates CVS Health (NYSE:CVS) with a Neutral and maintains $58 price target.